Source comparison
TB-500 vs. BPC-157: A Dosing Comparison
It's almost impossible to discuss TB-500 without mentioning its frequent research partner, BPC 157 Peptide. While both are studied for their regenerative properties, they operate through different mechanisms and their dosing protocols reflect that. BPC-157 is
This comparison does not assign a generated winner or score.
- It's almost impossible to discuss TB-500 without mentioning its frequent research partner, BPC 157 Peptide. While both are studied for their regenerative properties, they operate through different mechanisms and their dosing protocols reflect that. BPC-157 is known for its more localized effects, whereas TB-500 is considered more systemic.
- Here’s a high-level comparison of typical research approaches for these two compounds. We've seen them studied so often in tandem that we even offer a Wolverine Peptide Stack for researchers exploring their synergistic potential.
- Primary Action
- Systemic; promotes cell migration, angiogenesis, and modulates actin.
- More localized; promotes growth factor signaling and angiogenesis at specific sites.
- Common Vial Size
- 2mg, 5mg, 10mg
- 5mg, 10mg
- Typical Dosing Unit
- Milligrams (mg)
- Micrograms (mcg)
- Loading Phase
- Often used (e.g., 2.0-2.5mg, 2x/week) to achieve systemic saturation.
- Less common; dosing is typically consistent from the start of the study.
- Maintenance Phase
- Common practice (e.g., 2.0-2.5mg, 1x/week) to sustain levels.
- Dosing usually remains consistent throughout the research period.
- Frequency
- 1-3 times per week, depending on the phase.
- 1-2 times per day, often administered closer to the research site of injury.
- Example Dose
- 2.0 mg per administration
- 250-500 mcg per administration
- This table illustrates a key difference: BPC-157 protocols often involve smaller, more frequent administrations, while TB-500 protocols typically use larger doses administered less often. This is a direct reflection of their differing half-lives and mechanisms of action.